Ottimo Pharma Ltd.

https://www.ottimopharma.com

Ottimo Pharma is a private biotechnology company, co-founded in 2020 by Medicxi and Jonny Finlay, focused on the development of pioneering innovative cancer therapies for solid tumors. The Company’s lead program, Jankistomig, is a PD1-VEGFR2 bi-functional antibody designed to target both immune checkpoint inhibition and angiogenesis in a single IgG therapy. By advancing this dual-pathway approach, Ottimo Pharma aims to improve cancer treatment outcomes and reduce overall healthcare burden. The Company boasts a world-class leadership team, including David Epstein as Chair and CEO, Mehdi Shahidi as Head of Development and CMO, and James Sabry as Vice-Chair of the Board. Ottimo Pharma anticipates filing an IND in late 2025. *

	Start	2024-09-23 renamed
	Predecessor	Ultrahuman Eight Ltd.
	Industry	Jankistomig
	Industry 2	drug development
	Person	Epstein, David R. (Ottimo Pharma 202410– CEO before Seagen + Flagship Pioneering + >25 years at Novartis)
	Person 2	Sabry, James H. (Roche 201808– Global Head Partnering joined Genentech 2010 before Arete Therapeutics + Cytokinetics)

	Region	Sandwich, Kent
	Country	United Kingdom (GB)
	Street	Ramsgate Road c/o Kreston Reeves Llp, Innovation House
	City	CT13 9FF Sandwich, Kent
		Address record changed: 2024-10-31

Basic data	Employees	n. a.

		* Document for »About Section«: Ottimo Pharma Ltd.. (10/28/24). "Press Release: Ottimo Pharma Emerges from Stealth with Backing from Medicxi and Management Team Led by David Epstein to Accelerate Development of a Novel PD1/VEGFR2 Bi-Functional Antibody Planned to Enter the Clinic in 20

		Record changed: 2024-12-21

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x200px

More documents for Ottimo Pharma Ltd.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)